Tyra Biosciences Capital Raise of $400M
Tyra Biosciences entered into an underwriting agreement to raise approximately $400 million through the sale of 9,079,000 shares of common stock and 9,078,529 pre-funded warrants. The offering was led by RA Capital Management and includes participation from several institutional investors to fund the development of dabogratinib and other pipeline programs. The common stock is priced at $22.03 per share, with the offering expected to close on September 15, 2026.
- Value
- $400M
- Counterparty
- Jefferies LLC